Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...
        Saved in:
      
    
          | Main Authors: | Marco Donia, Rikke Andersen, Troels Holz Borch, Özcan Met, Eva Ellebaek, Inge Marie Svane | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | BMJ Publishing Group
    
        2020-10-01 | 
| Series: | Journal for ImmunoTherapy of Cancer | 
| Online Access: | https://jitc.bmj.com/content/8/2/e000668.full | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes        
                          
 by: Rikke Andersen, et al.
 Published: (2025-02-01)
- 
                
                    Biomarkers for response to TIL therapy: a comprehensive review        
                          
 by: Marco Donia, et al.
 Published: (2024-03-01)
- 
                
                    Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma        
                          
 by: Mario Sznol, et al.
 Published: (2020-05-01)
- 
                
                    18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma        
                          
 by: Tine Gadegaard Hindso, et al.
 Published: (2025-02-01)
- 
                
                    Clinical response to immune checkpoint inhibitors in immunocompromised patient with metastatic non-melanoma skin cancer        
                          
 by: P. Díaz Morales, et al.
 Published: (2024-01-01)
 
       